[ad_1]
Wedbush reaffirmed an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Wednesday.
[ad_2]
Source link
Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush
Related Posts
Nantahala Capital Management LLC Raises Holdings in COMPASS Pathways PLC Sponsored ADR $CMPS
[ad_1] Nantahala Capital Management LLC boosted its stake in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS – Free Report)…
BMO Capital Markets Has Lowered Expectations for Superior Plus (TSE:SPB) Stock Price
[ad_1] BMO Capital Markets lowered their price target on shares of Superior Plus from C$10.00 to C$8.00 and set an…
Viking Cruises Revenue Surges, Stock Dips 3%
[ad_1] Viking Today $58.42 -0.81 (-1.36%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io.…